A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
AMT-162-001
Phase 2 other active
Quick answer
A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) for Amyotrophic Lateral Sclerosis (ALS) is a Phase 2 program (other) at uniQure biopharma B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- uniQure biopharma B.V.
- Indication
- Amyotrophic Lateral Sclerosis (ALS)
- Phase
- Phase 2
- Modality
- other
- Status
- active